Heart Failure and Early Stage Chronic Kidney Disease -Mineral Bone Disorder : the Importance of the New Biomarkers
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 111
- 主要终点
- Fibroblast Growth Factor 23 (FGF23)
研究概览
简要总结
the objective of this study is to :
-Determinate wether the circulating levels of iFGF23 and klotho can be a predictor biomarker of HF in patients with CKD-MBD.
详细描述
The disorders of mineral metabolism and bone disease are common complications in CKD patients and they are associated with increased morbidity and mortality.
Abnormalities of the vasculature are seen in early CKD, producing vascular stiffness contributing to left ventricular hypertrophy and its pathophysiology involves newly discovered hormones, such as the fibroblast Growth factor 23 (FGF23) and α- klotho.
The FGF receptor and its co-receptor klotho moderate these effects. FGF23 levels inflate early in in the advancement of CKD stage to attain levels in CKD stage 5D.
But we still have few knoweledges if these markers can have some drawbacks for predicting CVD in early stage CKD.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Early CKD stage
- •Heart failure
排除标准
- •Infections
- •corticoid therapy
- •renal replacement therapy
- •Advanced CKD stage
结局指标
主要结局
Fibroblast Growth Factor 23 (FGF23)
时间窗: completed data base (after 4 months)
compare the circulating levels of FGF23 (pg/ml) in the two groups .
Alpha Klotho
时间窗: completed data base (after 4 months)
compare the circulating levels of klotho (ng/ml) in the two groups .
次要结局
未报告次要终点
研究者
Pr. Semir Nouira
Professor
University of Monastir